Kura Oncology Inc
About
Kura Oncology Inc (NASDAQ:KURA) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 24 2026
Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML
Apr 17 2026
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Apr 9 2026
Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026
Mar 5 2026
Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results
Feb 26 2026
Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results
Financials
Revenue
$67.48 M
Market Cap
$760.52 M
EPS
-3.18